#4089
Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome
Introduction:
Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.
Conference:
Presenting Author:
Maas C
Authors:
Maas C,
Mulders M,
Mirzaian M,
van den Berg S,
Brabander T,
Keywords:
carcinoid syndrome,
neuroendocrine tumor,
peptide receptor radionuclide therapy,
serotonin,
#4086
Prognostic significance of metabolomics clusters in extra-pancreatic NETs: Lung NET sub-analysis
Introduction:
Metabolic flexibility is one of the key hallmarks of cancer and metabolites are the final products of this adaptation, reflecting the aberrant changes that support cancer cells proliferation and survival. In a previous metabolomics study carried out by our group, multiplatform untargeted metabolomic profiling (GC-MS, CE-MS and LC-MS) performed on plasma samples from 77 advanced G1-2 extra-pancreatic NET patients demonstrated that these patients have a distinct metabolomic profile, and identified methionine, porphyrin and tryptophan metabolism as the most relevant dysregulated pathways associated with the prognosis of NETs. Furthermore, a 3-metabolite signature was able to stratify patients in 3 distinct prognostic clusters, with cluster 3 associated with the best prognosis.
Conference:
Presenting Author:
Authors:
La Salvia A,
Lens-Pardo A,
Carretero-Puche C,
Capdevila J,
Benavent M,
Keywords:
metabolimics,
prognostic biomarker,
lung neuroendocrine tumor,
metabolomic signature,
#2999
Aberrant Tryptophan Metabolism in Stromal Cells Is Associated with Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours
Introduction:
Increased levels of serotonin secretion are associated with mesenteric fibrosis (MF) in small intestinal neuroendocrine tumors (SI-NETs). However, only a proportion of patients with increased serotonin production will develop mesenteric fibrosis.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Blazevic A
Authors:
Blazevic A,
Iyer A,
Van Velthuysen M,
Hofland J,
Franssen G,
Keywords:
Small-intestinal neuroendocrine tumors,
mesenteric fibrosis,
serotonin,
tryptophan metabolism,
proteomics,
